A Phase 0/II Study of Ribociclib (LEE011) in Preoperative Rb-Positive Recurrent High-Grade Glioma and Meningioma Patients Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration
Phase of Trial: Phase 0
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Ribociclib (Primary)
- Indications Glioma; Meningioma
- Focus Pharmacodynamics; Pharmacokinetics
- 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 04 Jan 2017 Planned End Date changed from 1 Jan 2019 to 1 Apr 2019.
- 04 Jan 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Dec 2018.